Loss of Concurrent Regulation of the Expression of BIF-1, BAX, and Beclin-1 in Primary and Metastatic Melanoma.

Frangez, Z; Jafari, S M Seyed; Hunger, R E; Simon, H-U (2020). Loss of Concurrent Regulation of the Expression of BIF-1, BAX, and Beclin-1 in Primary and Metastatic Melanoma. Biochemistry (Moscow), 85(10), pp. 1227-1234. Pleiades 10.1134/S0006297920100107

[img] Text
Frange__2020_Article_LossOfConcurrentRegulationOfTh.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (2MB) | Request a copy
[img]
Preview
Text
Biochemistry__Moscow__Simon__3_.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (522kB) | Preview

Melanoma is one of the most aggressive and drug-resistant cancers. Despite novel promising therapeutic strategies, the prognosis of metastatic melanoma patients remains poor and it is often associated with high relapse rates. Endophilin B1, also known as BIF-1, is a multifunctional protein involved in several biological processes such as autophagy and apoptosis. BIF-1 promotes apoptosis through binding to BAX and its translocation to the mitochondrial outer membrane. On the other hand, BIF-1 can interact with Beclin-1 through UVRAG to promote autophagy. Several reports suggest an ambiguous role of BIF-1 in cancer development and progression. For example, it has been demonstrated that the expression of BIF-1 is reduced in both primary and metastatic melanoma and that the reduction of BIF-1 expression is associated with reduced overall survival of melanoma patients. Here we show that the expression of Beclin-1 and active form of BAX are also reduced in the melanoma patients. However, while we observed strong positive correlations between the expression of BIF-1 and Beclin-1 as well as between BIF-1 and BAX in benign nevi, these correlations were lost in the primary and metastatic melanoma cells. These data indicate disruption in the proximal molecular mechanisms which regulate expression of BIF-1, Beclin-1, and BAX in the primary and metastatic melanoma.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Pharmacology
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Frangez, Ziva; Jafari, Morteza; Hunger, Robert and Simon, Hans-Uwe

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0006-2979

Publisher:

Pleiades

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

04 Jan 2021 15:25

Last Modified:

18 Feb 2021 08:33

Publisher DOI:

10.1134/S0006297920100107

PubMed ID:

33202207

BORIS DOI:

10.48350/149462

URI:

https://boris.unibe.ch/id/eprint/149462

Actions (login required)

Edit item Edit item
Provide Feedback